Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
At a glance
- Drugs AMG 594 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 01 Nov 2018 According to a Cytokinetics media release, the company expects to initiate this trial before the end of the year 2018.
- 25 Oct 2018 New trial record
- 16 Oct 2018 According to a Cytokinetics media release, IND has been filed.